Psychedelics
Mind Medicine Australia Webinar : Helping to change policy – Influencing the TGA with Prof. David Nutt (UK)
Don’t miss out – Get your tickets early!
Join this FREE, 75-minute online webinar to gain access to insights and learn about ground-breaking treatments to chronic mental health conditions.
FREE WEBINAR: Helping to change policy – Influencing the TGA with Professor David Nutt (UK)
What we know, what we think, and what we need to research
Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this field with many tens of new pharmaceutical companies being set up to research the effects of known psychedelics and develop new patentable molecules. Whilst this enthusiasm is to be welcomed, it is important that new research is properly grounded in established facts and reflects current knowledge.
In this webinar, Professor Nutt will discuss:
- The safety of these medicines
- The new neuroscience showing how they work
- The compelling growth in clinical evidence and the growing needs
WEBINAR SESSION
Date: Wednesday 15 February 2023
Time: 7:55pm for 8:00pm start – 9:15pm (incl Q&A) (AEDT)
The presentation WILL BEGIN AT 8:00pm. (AEDT)
Location: Online. A link will be emailed to you with the viewing details.
Support these events:
Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.
More about Mind Medicine Australia and medicinal psychedelic–assisted therapy:
Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients.
Unlike current treatments such as anti-depressants, which only manage the illness and can have nasty side effects, psilocybin and MDMA assisted therapies have been scientifically proven to be a safe and effective cure for anxiety, depression, end-of-life stress, addictions and PTSD after just a short treatment program. These medicines are also currently being researched for dementia, eating disorders, OCD and a number of other conditions. Both medicines have been granted Breakthrough Therapy Status by the FDA in the USA to fast-track their approval. This designation is only given to medicines which may prove to be vastly superior to existing treatments.
At Mind Medicine Australia we are dedicated to helping the now global movement to spread this awareness and ensure these medicines are available via the medical system. Please watch and share our 2 minute animation to find out why psychedelic-assisted psychotherapy needs to be available to those who are suffering.
More about the presenters
Prof David Nutt (UK)
BA, MB BChir, MRCP, MA, DM, MRC Psych, FRCPsych, FMedSci, FRCP, FSB
Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London and the Chair of Drug Science.
Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.
Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.
He was previously Chair of the UK Advisory Council on the Misuse of Drugs.
Support psychedelic research and therapy development
By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.
Disclaimer
Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.
Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.